35,500 Shares in Edwards Lifesciences Corporation $EW Acquired by Van Hulzen Asset Management LLC

Van Hulzen Asset Management LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 35,500 shares of the medical research company's stock, valued at approximately $3,211,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Edwards Lifesciences during the second quarter valued at approximately $5,318,092,000. Norges Bank purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $803,686,000. Conway Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $954,000. TD Asset Management Inc grew its position in shares of Edwards Lifesciences by 6.4% during the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company's stock valued at $66,335,000 after acquiring an additional 47,051 shares during the period. Finally, Varma Mutual Pension Insurance Co bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $11,168,000. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on EW. Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Barclays restated an "overweight" rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Evercore reiterated an "outperform" rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research note on Thursday, July 16th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Insider Activity

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company's stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Up 0.8%

NYSE EW opened at $90.53 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market capitalization of $52.13 billion, a P/E ratio of 52.03, a P/E/G ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The stock has a 50 day moving average price of $89.30 and a 200-day moving average price of $84.74.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same period in the prior year, the company earned $0.67 EPS. The business's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source